secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123255
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024
--------------------------------------------------------------------------------

- Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.
- Cash, equivalents and investments $342.6M as of Sept 30, 2024; projected runway into 2H 2027.
- Initiation of pivotal Phase 3 CIDP trial (single, two-part, randomized withdrawal) expected by year-end 2024.
- Phase 2 MaGic gMG trial on track for top-line data 2H 2025; Phase 2 MoMeNtum MMN trial for 2H 2026.
- Steven Romano, M.D., appointed to board effective Sept 16, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/0000950170-24-123255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer